When you have inactive secondary-progressive multiple sclerosis (SPMS), it may seem like no news is good news. But the lack of relapses can be misleading. Although things may seem quiet, there may ...

If you have inactive secondary progressive multiple sclerosis (SPMS), you know firsthand that it can be difficult to manage. Unlike active SPMS, where you see clear signs of new relapses, inactive ...

Improvements in safety, efficacy, and specificity have raised questions around the benefits and risks of switching treatments for this type of MS, especially from fingolimod to siponimod. There are ...

Continued advancements in treatment and care are improving outcomes for people with MS. Multiple sclerosis (MS) develops when your immune system mistakenly attacks myelin, the protective coating that ...

COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS). The Phase 3 HERCULES ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple sclerosis (MS). PRLs are thought to capture a subset of chronic ...

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering ...

Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes” The ...